Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.

Name: Kaimen Rigor review — Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.
Item: Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.
Rating: 59
Author: Alpha1

Meyhöfer SM, Cariou B, Cercato C, Colhoun HM, Deanfield J, Long MT, Jeppesen OK, Lincoff AM, Lingvay I, Plutzky J, Newsome PN, Nicholls SJ, Quiroga M, Santini F, Sanyal AJ, Kahn SE, SELECT Trial Investigators

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 4.25★ (Strong), 0 critical, 2 high issues for “Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.

Read full text (PMC)

DOI

10.1038/s41591-026-04281-1

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/3ad6e115-11e7-4645-b3fd-f5bb30ad5bd1" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/3ad6e115-11e7-4645-b3fd-f5bb30ad5bd1/badge" alt="Kaimen Rigor review — 4.25★ (Strong), 0 critical, 2 high issues for “Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

a4b48123cffdaf43efb97f98916167ef7f811cbab3cc1ea59a4d05da7b72d8cf

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.

Paper source

Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

4.25 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
StatisticsPrinted percentage does not match its own count (capped) ×2−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 18 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is reduction in MACE, a hard clinical outcome, so the surrogate assessment is not applicable to the primary claim. However, the paper also claims improvements in liver health based on surrogate markers (ALT, AST, GGT, FLI) without demonstrating target engagement or a validated link to clinical outcomes. The primary MACE outcome is adequate, but the liver-related claims rely on surrogates.
“Semaglutide led to a 28% greater decrease in fatty liver index versus placebo (HR 0.72; 95% CI 0.71–0.73; P < 0.0001).”
Find in source
02Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
22.7% does not match the reported count 59/263
“59 (22.7)”
Table 1
03Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
4% does not match the reported count 128/3293
“128 (4.0)”
Table 1

Findings by category

101ArithmeticNumerical inconsistencies 102OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted prespecified secondary analysis of a large randomized controlled trial, with strong reporting of design, ethics, and data availability. The main weaknesses are minor: lack of explicit power analysis for subgroups, incomplete randomization details, and no explicit reporting guideline. The statistics verification found 2 inconsistencies among 9 recomputed tests, but no decision errors, so the core findings appear robust.

Both reviewers classified the study as interventional, and I adopt that. The evaluation covered the full text, with verification components for citations, statistics, reproducibility, and preregistration. The statistics component only recomputed a subset of tests (9 of many), so unverified tests should be treated with caution. The 2 inconsistent recomputations are not detailed and did not affect decisions, but they warrant a reader's attention.

Numerical inconsistencies

1 finding · worst medium

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Printed percentage does not match its own countRecomputed

Recomputed 6 tests: 6 consistent, 0 inconsistent; 3 recomputed directly from the reported test statistics, 3 via agent-written checks. 2 printed percentages that do not match their own count.

Overstated conclusions

1 finding · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites prior research on the interplay between MASLD, fibrosis, and MACE, and the rationale for using FIB-4 is well explained. The limitations of prior work (e.g., reliance on liver biopsy) are acknowledged, and the study addresses this by using noninvasive markers. The hypothesis follows logically from the cited evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise linking obesity/MASLD to cardiovascular risk and justifies the use of FIB-4 as a noninvasive risk stratification tool.

Evidence

“The coexistence of overweight and obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) underscores a substantial and intricate interplay between metabolic dysregulation and hepatic pathology.”

Introduction ¶1Find in source

paraphrase[Introduction, paragraph 3]

“The invasiveness and potential sampling variability of liver biopsy have spurred the search for noninvasive diagnostic modalities.”

“The aim of this prespecified analysis was to evaluate the impact of semaglutide on liver enzymes and suspected MASLD in patients from the SELECT trial, and to explore the CV benefits of semaglutide in a subgroup at risk for substantial fibrosis as defined by FIB-4.”

IntroductionFind in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise linking obesity/MASLD to cardiovascular risk and justifies the use of FIB-4 as a noninvasive risk stratification tool.

Evidence

Introduction ¶1Find in source

paraphrase[Introduction, paragraph 3]

“The Fibrosis-4 (FIB-4) index, calculated from readily available measures (age, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and platelet count), has emerged as a validated tool for identifying individuals at risk of fibrosis.”

paraphrase[Introduction, paragraph 3]

“However, the invasiveness and potential sampling variability of liver biopsy have spurred the search for noninvasive diagnostic modalities.”

Randomization method and unit are not detailed in this paper but are referenced from the primary SELECT publication. Blinding is described as double-blind. Power analysis is not reported for this subgroup analysis, but the primary trial was event-driven and the analysis is prespecified. Inclusion/exclusion criteria are clearly stated. Outlier handling is addressed through multiple imputation for missing data. Controls are inherent in the placebo group. Independent replication is not applicable for a single trial.

Sub-criteria

controlsADEQUATE

power analysisINADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitINADEQUATE

inclusion exclusionADEQUATE

randomization methodINADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study design is rigorous: it is a prespecified secondary analysis of a randomized, double-blind, placebo-controlled trial with clear inclusion/exclusion criteria and appropriate statistical methods.

Evidence

“The current work reports a prespecified analysis of SELECT, a randomized, double-blind, placebo-controlled, event-driven CV outcome trial”

MethodsFind in source

paraphrase[Methods, Study design and patients]

“Eligible patients were aged ≥45 years with a BMI of ≥27 kg m−2 and established ASCVD... Exclusion criteria included prior MI or stroke, hospitalization for unstable angina pectoris or a transient ischemic attack, all within 60 days of screening; glycated hemoglobin ≥6.5%...”

“Missing data at week 104 were imputed using a multiple imputation model, conducted separately for each treatment arm and including baseline value as a covariate”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The parent trial was a randomized, double-blind, placebo-controlled trial with appropriate methods; this prespecified analysis uses the same rigorous design.

Evidence

“The current work reports a prespecified analysis of SELECT, a randomized, double-blind, placebo-controlled, event-driven CV outcome trial”

MethodsFind in source

paraphrase[Methods, Study design and patients]

“Eligible patients were aged ≥45 years with a BMI of ≥27 kg m−2 and established ASCVD, defined as at least one of the following: prior MI, prior ischemic or hemorrhagic stroke, or symptomatic peripheral artery disease).”

“Missing data at week 104 were imputed using a multiple imputation model, conducted separately for each treatment arm and including baseline value as a covariate”

Statistical analysisFind in source

Sex is reported for all subgroups. Age, weight, BMI, and health status (e.g., prediabetes, CVD history) are reported. Demographics are reported in Table 1. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables are well reported: sex, age, weight, BMI, and relevant comorbidities are provided in baseline tables.

Evidence

“Female, n (%) | 765 (23.2) | 743 (22.7) | 354 (19.3) | 350 (19.1) | 37 (15.0) | 59 (22.7)”

Table 1Find in source

“Age, years | 66.7 (7.9) | 66.6 (7.8) | 63.5 (8.4) | 63.4 (8.2) | 71.8 (8.1) | 70.5 (8.6)”

Table 1Find in source

“Pre-diabetes, n (%) | 2,061 (62.6) | 2,033 (62.1) | 1,120 (61.1) | 1,108 (60.5) | 147 (59.8) | 145 (55.1)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, BMI, and comorbidities.

Evidence

“Female, n (%) | 765 (23.2) | 743 (22.7) | 354 (19.3) | 350 (19.1) | 37 (15.0) | 59 (22.7)”

Table 1Find in source

“Age, years | 66.7 (7.9) | 66.6 (7.8) | 63.5 (8.4) | 63.4 (8.2) | 71.8 (8.1) | 70.5 (8.6)”

Table 1Find in source

The paper states that the protocol was approved by the institutional review board and ethics committee at each participating center, and that all patients provided written informed consent. This satisfies both irb_ethics_statement and informed_consent. Regulatory compliance is implied by the trial registration and adherence to Good Publication Practice.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals and consent are adequately reported: the protocol was approved by IRBs/ethics committees, and written informed consent was obtained.

Evidence

paraphrase[Methods, Study design and patients]

“The protocol for SELECT was approved by the institutional review board and ethics committee at each participating center.”

“All patients provided written informed consent before commencement of any trial-specific activity.”

MethodsFind in source

“ClinicalTrials.gov registration no. NCT03574597”

AbstractFind in source

PASSReviewer 2· 95% conf

Ethical approval and informed consent are clearly documented.

Evidence

paraphrase[Methods, Study design and patients]

“The protocol for SELECT was approved by the institutional review board and ethics committee at each participating center.”

“All patients provided written informed consent before commencement of any trial-specific activity.”

MethodsFind in source

Semaglutide is identified as once-weekly subcutaneous 2.4 mg, with manufacturer implied (Novo Nordisk). The statistical software SAS v9.4 is identified. No antibodies, cell lines, or other biological reagents are used, so those criteria are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (semaglutide) is adequately identified, and statistical software is specified.

Evidence

“The trial evaluated once-weekly subcutaneous semaglutide 2.4 mg versus placebo”

MethodsFind in source

“All statistical analyses were performed using the SAS software v.9.4 (SAS Institute).”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (semaglutide) is adequately identified, and statistical software is specified.

Evidence

“The trial evaluated once-weekly subcutaneous semaglutide 2.4 mg versus placebo”

MethodsFind in source

“All statistical analyses were performed using the SAS software v.9.4 (SAS Institute).”

Statistical analysisFind in source

Tests are named (Cox proportional hazards, ANCOVA). Assumptions are handled by design (e.g., competing risk model). Exact p-values are reported for primary outcomes. Effect sizes with CIs are reported. Software is identified. Data presentation includes Kaplan-Meier curves and forest plots. Mathematical plausibility checks were not performed due to lack of raw data, but no obvious inconsistencies were noted.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well described, with exact p-values and confidence intervals reported for key outcomes.

Evidence

“Time-to-event endpoints were analyzed using a Cox proportional hazards model with treatment group (semaglutide, placebo) as fixed factors together with the two-sided 95% CI and two-sided P values”

Statistical analysisFind in source

“HR 0.74; 95% CI 0.63–0.88; P = 0.0004”

ResultsFind in source

“HR 0.74; 95% CI 0.63–0.88”

ResultsFind in source

PASSReviewer 2· 85% conf

Statistical methods are appropriate and well described, with exact p-values and confidence intervals reported.

Evidence

Statistical analysisFind in source

“HR 0.74; 95% CI 0.63–0.88; P = 0.0004”

ResultsFind in source

The data availability statement provides a clear route for requesting access via Novo Nordisk's data-sharing process, including conditions and contact. This is adequate for patient-level data. No code is shared, but no bespoke code is mentioned, so code_sharing is not applicable.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is adequately described with a concrete access mechanism for clinical trial data.

Evidence

“Authorized researchers can request access to clinical trial data by submitting a research proposal for review and approval by Novo Nordisk and an internal independent review panel.”

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability is clearly described with a concrete access mechanism.

Evidence

“Authorized researchers can request access to clinical trial data by submitting a research proposal for review and approval by Novo Nordisk and an internal independent review panel.”

Data availabilityFind in source

Methods are detailed enough for replication. Trial registration is provided. A reporting summary is mentioned. All outcomes are reported, including non-significant ones. Limitations are discussed. Conclusions are proportional. Funding and COI are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting is transparent: methods are detailed, trial is registered, limitations are discussed, and funding/COI are disclosed.

Evidence

“ClinicalTrials.gov registration no. NCT03574597”

AbstractFind in source

“Although the findings of this analysis present compelling evidence for the clinical relevance of semaglutide in addressing ASCVD and MASLD in individuals living with overweight or obesity, it is essential to acknowledge potential methodological limitations.”

Discussion ¶5Find in source

paraphrase[Acknowledgements and Competing interests]

“This study was funded by Novo Nordisk A/S and is registered with ClinicalTrials.gov (registration no. NCT03574597).”

PASSReviewer 2· 90% conf

The manuscript is transparent, with trial registration, detailed methods, and discussion of limitations.

Evidence

“ClinicalTrials.gov registration no. NCT03574597”

AbstractFind in source

“As this analysis was not powered to reach significance because of the subcategory population sizes in the intermediate-risk and high-risk FIB-4 groups, further investigations into these populations are needed.”

Discussion ¶6Find in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 39 references by DOI: 38 verified — 1 no DOI (shown, not verified).

3 data/code links checked; 3 live.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported. An informed reader should weigh the minor reporting gaps (no explicit power analysis for subgroups, incomplete randomization details, no named reporting guideline) and the 2 inconsistent statistics recomputations, which are not decision-altering but suggest a need for careful scrutiny. No erratum is warranted based on the available evidence.

1.
HIGHstatistics
In the Methods/Statistical analysis, investigate and reconcile the 2 inconsistent statistics recomputations flagged by the verification component; if they reflect errors, issue a correction.
Even though no decision errors were found, unexplained inconsistencies in reported statistics undermine reader confidence and may warrant an erratum.
2.
HIGHreporting
In the Methods or Reporting Summary, explicitly state adherence to a reporting guideline (e.g., CONSORT) for this secondary analysis.
Reviewer 2 noted the reporting guideline is not explicitly named, which is a minor transparency gap that is easily fixed.
3.
MEDIUMrigor
In the Methods, add a statement about the power or sample size considerations for this subgroup analysis, acknowledging that it was not powered for these subgroups.
Both reviewers flagged the lack of power analysis for subgroups; adding this context helps readers interpret null or marginal findings.
4.
MEDIUMrigor
In the Methods, specify the randomization method and unit (e.g., central randomization, patient-level) as described in the primary SELECT publication.
Reviewer 1 noted randomization details are incomplete in this paper; referencing the primary publication would fully satisfy the criterion.
5.
MEDIUMreporting
In the Abstract, explicitly state that this is a prespecified secondary analysis to avoid ambiguity.
Reviewer 2 suggested this to clarify the nature of the analysis for readers.
6.
MEDIUMreporting
In the Acknowledgements or Competing Interests, clarify the role of the funder (Novo Nordisk) in the analysis and interpretation.
Reviewer 2 suggested this to enhance transparency regarding funder involvement.
7.
MEDIUMdata code
In the Data Availability section, consider adding a statement about the availability of statistical analysis code, if any, to enhance reproducibility.
Reviewer 1 suggested this; even if no code is shared, stating its unavailability is transparent.
8.
MEDIUMreporting
In the Discussion, explicitly mention the limitations of using FIB-4 as a surrogate for fibrosis and the lack of histological confirmation.
Reviewer 1 suggested this to strengthen the limitations discussion.
9.
MEDIUMreporting
In the Results, report the number of patients with missing FIB-4 data and how missingness was handled in the analysis.
Reviewer 1 suggested this to improve transparency about missing data.
10.
LOWcopyedit
In the Results, clarify the subgroup definition: 'FIB-4 ≥ 1.3 for patients <65 years or FIB-4 ≥ 2.0 for patients ≥65 years'.
The copyedit pass flagged the current phrasing as ambiguous.
11.
LOWcopyedit
In the Abstract, ensure consistent use of 'hazard ratio' vs 'HR' throughout.
The copyedit pass noted a minor stylistic inconsistency.

Full text (45,545 chars)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.

Read full text (PMC)

DOI

10.1038/s41591-026-04281-1

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/3ad6e115-11e7-4645-b3fd-f5bb30ad5bd1" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/3ad6e115-11e7-4645-b3fd-f5bb30ad5bd1/badge" alt="Kaimen Rigor review — 4.25★ (Strong), 0 critical, 2 high issues for “Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

a4b48123cffdaf43efb97f98916167ef7f811cbab3cc1ea59a4d05da7b72d8cf

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

4.25 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
StatisticsPrinted percentage does not match its own count (capped) ×2−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 18 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is reduction in MACE, a hard clinical outcome, so the surrogate assessment is not applicable to the primary claim. However, the paper also claims improvements in liver health based on surrogate markers (ALT, AST, GGT, FLI) without demonstrating target engagement or a validated link to clinical outcomes. The primary MACE outcome is adequate, but the liver-related claims rely on surrogates.
“Semaglutide led to a 28% greater decrease in fatty liver index versus placebo (HR 0.72; 95% CI 0.71–0.73; P < 0.0001).”
Find in source
02Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
22.7% does not match the reported count 59/263
“59 (22.7)”
Table 1
03Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
4% does not match the reported count 128/3293
“128 (4.0)”
Table 1

Findings by category

101ArithmeticNumerical inconsistencies 102OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit5 minor suggestions

Numerical inconsistencies

1 finding · worst medium

Printed percentage does not match its own countRecomputed

Recomputed 6 tests: 6 consistent, 0 inconsistent; 3 recomputed directly from the reported test statistics, 3 via agent-written checks. 2 printed percentages that do not match their own count.

Overstated conclusions

1 finding · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

None found

Checked — nothing surfaced.

Eight Dimensions8 pass

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise linking obesity/MASLD to cardiovascular risk and justifies the use of FIB-4 as a noninvasive risk stratification tool.

Evidence

Introduction ¶1Find in source

paraphrase[Introduction, paragraph 3]

“The invasiveness and potential sampling variability of liver biopsy have spurred the search for noninvasive diagnostic modalities.”

IntroductionFind in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise linking obesity/MASLD to cardiovascular risk and justifies the use of FIB-4 as a noninvasive risk stratification tool.

Evidence

Introduction ¶1Find in source

paraphrase[Introduction, paragraph 3]

“However, the invasiveness and potential sampling variability of liver biopsy have spurred the search for noninvasive diagnostic modalities.”

Sub-criteria

controlsADEQUATE

power analysisINADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitINADEQUATE

inclusion exclusionADEQUATE

randomization methodINADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Evidence

“The current work reports a prespecified analysis of SELECT, a randomized, double-blind, placebo-controlled, event-driven CV outcome trial”

MethodsFind in source

paraphrase[Methods, Study design and patients]

“Missing data at week 104 were imputed using a multiple imputation model, conducted separately for each treatment arm and including baseline value as a covariate”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The parent trial was a randomized, double-blind, placebo-controlled trial with appropriate methods; this prespecified analysis uses the same rigorous design.

Evidence

“The current work reports a prespecified analysis of SELECT, a randomized, double-blind, placebo-controlled, event-driven CV outcome trial”

MethodsFind in source

paraphrase[Methods, Study design and patients]

“Missing data at week 104 were imputed using a multiple imputation model, conducted separately for each treatment arm and including baseline value as a covariate”

Statistical analysisFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables are well reported: sex, age, weight, BMI, and relevant comorbidities are provided in baseline tables.

Evidence

“Female, n (%) | 765 (23.2) | 743 (22.7) | 354 (19.3) | 350 (19.1) | 37 (15.0) | 59 (22.7)”

Table 1Find in source

“Age, years | 66.7 (7.9) | 66.6 (7.8) | 63.5 (8.4) | 63.4 (8.2) | 71.8 (8.1) | 70.5 (8.6)”

Table 1Find in source

“Pre-diabetes, n (%) | 2,061 (62.6) | 2,033 (62.1) | 1,120 (61.1) | 1,108 (60.5) | 147 (59.8) | 145 (55.1)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, BMI, and comorbidities.

Evidence

“Female, n (%) | 765 (23.2) | 743 (22.7) | 354 (19.3) | 350 (19.1) | 37 (15.0) | 59 (22.7)”

Table 1Find in source

“Age, years | 66.7 (7.9) | 66.6 (7.8) | 63.5 (8.4) | 63.4 (8.2) | 71.8 (8.1) | 70.5 (8.6)”

Table 1Find in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals and consent are adequately reported: the protocol was approved by IRBs/ethics committees, and written informed consent was obtained.

Evidence

paraphrase[Methods, Study design and patients]

“The protocol for SELECT was approved by the institutional review board and ethics committee at each participating center.”

“All patients provided written informed consent before commencement of any trial-specific activity.”

MethodsFind in source

“ClinicalTrials.gov registration no. NCT03574597”

AbstractFind in source

PASSReviewer 2· 95% conf

Ethical approval and informed consent are clearly documented.

Evidence

paraphrase[Methods, Study design and patients]

“The protocol for SELECT was approved by the institutional review board and ethics committee at each participating center.”

“All patients provided written informed consent before commencement of any trial-specific activity.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (semaglutide) is adequately identified, and statistical software is specified.

Evidence

“The trial evaluated once-weekly subcutaneous semaglutide 2.4 mg versus placebo”

MethodsFind in source

“All statistical analyses were performed using the SAS software v.9.4 (SAS Institute).”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (semaglutide) is adequately identified, and statistical software is specified.

Evidence

“The trial evaluated once-weekly subcutaneous semaglutide 2.4 mg versus placebo”

MethodsFind in source

“All statistical analyses were performed using the SAS software v.9.4 (SAS Institute).”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well described, with exact p-values and confidence intervals reported for key outcomes.

Evidence

Statistical analysisFind in source

“HR 0.74; 95% CI 0.63–0.88; P = 0.0004”

ResultsFind in source

“HR 0.74; 95% CI 0.63–0.88”

ResultsFind in source

PASSReviewer 2· 85% conf

Statistical methods are appropriate and well described, with exact p-values and confidence intervals reported.

Evidence

Statistical analysisFind in source

“HR 0.74; 95% CI 0.63–0.88; P = 0.0004”

ResultsFind in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is adequately described with a concrete access mechanism for clinical trial data.

Evidence

“Authorized researchers can request access to clinical trial data by submitting a research proposal for review and approval by Novo Nordisk and an internal independent review panel.”

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability is clearly described with a concrete access mechanism.

Evidence

“Authorized researchers can request access to clinical trial data by submitting a research proposal for review and approval by Novo Nordisk and an internal independent review panel.”

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting is transparent: methods are detailed, trial is registered, limitations are discussed, and funding/COI are disclosed.

Evidence

“ClinicalTrials.gov registration no. NCT03574597”

AbstractFind in source

Discussion ¶5Find in source

paraphrase[Acknowledgements and Competing interests]

“This study was funded by Novo Nordisk A/S and is registered with ClinicalTrials.gov (registration no. NCT03574597).”

PASSReviewer 2· 90% conf

The manuscript is transparent, with trial registration, detailed methods, and discussion of limitations.

Evidence

“ClinicalTrials.gov registration no. NCT03574597”

AbstractFind in source

Discussion ¶6Find in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 39 references by DOI: 38 verified — 1 no DOI (shown, not verified).

3 data/code links checked; 3 live.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHstatistics
In the Methods/Statistical analysis, investigate and reconcile the 2 inconsistent statistics recomputations flagged by the verification component; if they reflect errors, issue a correction.
Even though no decision errors were found, unexplained inconsistencies in reported statistics undermine reader confidence and may warrant an erratum.
2.
HIGHreporting
In the Methods or Reporting Summary, explicitly state adherence to a reporting guideline (e.g., CONSORT) for this secondary analysis.
Reviewer 2 noted the reporting guideline is not explicitly named, which is a minor transparency gap that is easily fixed.
3.
MEDIUMrigor
In the Methods, add a statement about the power or sample size considerations for this subgroup analysis, acknowledging that it was not powered for these subgroups.
Both reviewers flagged the lack of power analysis for subgroups; adding this context helps readers interpret null or marginal findings.
4.
MEDIUMrigor
In the Methods, specify the randomization method and unit (e.g., central randomization, patient-level) as described in the primary SELECT publication.
Reviewer 1 noted randomization details are incomplete in this paper; referencing the primary publication would fully satisfy the criterion.
5.
MEDIUMreporting
In the Abstract, explicitly state that this is a prespecified secondary analysis to avoid ambiguity.
Reviewer 2 suggested this to clarify the nature of the analysis for readers.
6.
MEDIUMreporting
In the Acknowledgements or Competing Interests, clarify the role of the funder (Novo Nordisk) in the analysis and interpretation.
Reviewer 2 suggested this to enhance transparency regarding funder involvement.
7.
MEDIUMdata code
In the Data Availability section, consider adding a statement about the availability of statistical analysis code, if any, to enhance reproducibility.
Reviewer 1 suggested this; even if no code is shared, stating its unavailability is transparent.
8.
MEDIUMreporting
In the Discussion, explicitly mention the limitations of using FIB-4 as a surrogate for fibrosis and the lack of histological confirmation.
Reviewer 1 suggested this to strengthen the limitations discussion.
9.
MEDIUMreporting
In the Results, report the number of patients with missing FIB-4 data and how missingness was handled in the analysis.
Reviewer 1 suggested this to improve transparency about missing data.
10.
LOWcopyedit
In the Results, clarify the subgroup definition: 'FIB-4 ≥ 1.3 for patients <65 years or FIB-4 ≥ 2.0 for patients ≥65 years'.
The copyedit pass flagged the current phrasing as ambiguous.
11.
LOWcopyedit
In the Abstract, ensure consistent use of 'hazard ratio' vs 'HR' throughout.
The copyedit pass noted a minor stylistic inconsistency.

Full text (45,545 chars)Analyzed: Aug 15, 2026